Clinical Trials Logo

Filter by:
NCT ID: NCT03863262 Completed - Depression Clinical Trials

SCREENING FOR DEPRESSION IN CARDIOVASCULAR PATIENTS AT A TERTIARY CENTRE IN TRINIDAD AND TOBAGO

SAD CAD TNT
Start date: November 8, 2018
Phase:
Study type: Observational

This was an observational study aimed to screen patients with cardiovascular disease for depression in Trinidad and Tobago in a tertiary center and to determine if there is a significant association between patients with symptoms of depression and other comorbidities. Patients (N=1203) were randomly selected from the outpatient cardiology clinics at the Eric Williams Medical Sciences Complex. After fulfilling the inclusion criteria and informed consent were obtained, they were given the case report form which included the Patient Health Questionnaire 9.

NCT ID: NCT03667066 Completed - Clinical trials for Platelet Dysfunction

clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad

POINT
Start date: September 1, 2017
Phase:
Study type: Observational

The aim of this study was to determine the prevalence of clopidogrel resistance among a selected group of patients undergoing elective percutaneous coronary intervention and to observe whether there was any south-Asian (Indo-Trinidadian) predilection for HPR considering the well-established epidemiologic trends for accelerated CAD within this subgroup.

NCT ID: NCT03603249 Active, not recruiting - Clinical trials for Platelet Dysfunction Due to Drugs

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

TRACER
Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

Hypothesis: Trimetazidine improves Clopidogrel response in patients. • The investigators postulate that the inhibition of platelet aggregation in response to Clopidogrel may be accentuated by Trimetazidine, i.e. Trimetazidine enhances Clopidogrel response. Null Hypothesis: There is no difference in Clopidogrel response in patients with stable coronary artery disease with adjunctive Trimetazidine.

NCT ID: NCT03258723 Not yet recruiting - Diabetes Clinical Trials

Diabetes Prevention With Lifestyle Intervention and Metformin Escalation

LIME
Start date: June 30, 2018
Phase: Phase 4
Study type: Interventional

Specific Aim: Implement an evidence-based diabetes prevention pragmatic trial for high risk pre-diabetic individuals of Caribbean-descent to reduce the incidence of diabetes. Hypothesis: This study seeks to test the hypothesis that implementation of a lifestyle intervention, with escalation to Metformin therapy will lower the incidence of diabetes among the highest risk pre-diabetic individuals of Caribbean-descent.

NCT ID: NCT02979938 Completed - Zika Virus Clinical Trials

Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection

Start date: July 2016
Phase:
Study type: Observational

In this prospective observational study the investigators will report on 20 male subjects with proven WHO-classification Zika infection. These subjects will be followed up for a maximum of 12 months to observe the presence, viral load and infectivity of Zika virus (ZIKV) in semen over time.

NCT ID: NCT02587806 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI).

NCT ID: NCT02587715 Recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT02418351 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI).

NCT ID: NCT02418325 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment. Secondary objective: Assessment of efficacy at baseline, prior to discharge, 1 month, 3 months, 6 months and 12 months after treatment based on the following: EDSS and 29-item Multiple Sclerosis Impact Scale (MSIS-29), MS Functional Composite (MSFC) consisting of (1) Timed 25-Foot Walk, (2) 9 Hole Peg Test, and (3) Paced Auditory Serial Addition Test and gadolinium-enhanced magnetic resonance imaging (MRI)

NCT ID: NCT01994811 Recruiting - Diabetes Clinical Trials

Eastern Caribbean Health Outcomes Research Network (ECHORN)

ECHORN
Start date: April 2013
Phase: N/A
Study type: Observational

The Eastern Caribbean Health Outcomes Research Network (ECHORN) is a collaborative research study that examines the lifestyles, eating habits, and health behaviors associated with cancer, diabetes and heart disease in adult men and women living in the Eastern Caribbean.